Oculis Shifts Licaminlimab Strategy Toward Precision Dry Eye Treatment

Oculis is changing the commercial strategy for its dry eye candidate, Licaminlimab. The company is moving away from a broad-market approach to focus on a precision medicine model targeting TNFR1-positive patients. With a $282 million cash balance, the company intends to use this repositioning to support higher pricing and targeted market access through 2029.

"The company now thinks of the drug not as a broad dry eye product, but as a treatment for a defined biomarker-positive population," said Dr. Riad Sherif, Chief Executive of Oculis, at the H.C. Wainwright conference.

Clinical Data and Biomarker Strategy

The strategic pivot follows Phase II clinical data showing a disparity in patient outcomes based on biomarker status. According to a transcript of the H.C. Wainwright conference, the TNFR1-positive population demonstrated a 28-point improvement on the visual analog scale. This compares to a 4-point improvement in the unselected patient population.

Dr. Sherif indicated that a more restrictive regulatory label resulting from this targeted approach is viewed as an upside. By focusing on a specific biomarker, the company aims to establish a personalized medicine model that justifies premium pricing and access for the patients most likely to respond to the therapy.

Financial Runway and Clinical Pipeline

Oculis reported a cash position of $282 million, which the company expects will provide a financial runway into the second half of 2029. This capital is earmarked to fund key clinical trials, including the PREDICT-1 study and the neurology-focused PIONEER-1, 2, and 3 trials.

As of September 16, 2026, shares of Oculis (OCS) were trading at $9.78, representing a decline of 2.88%.

What Is at Stake for Oculis

For investors and clinicians, the transition marks a departure from the traditional blockbuster drug model in ophthalmology toward a niche-focused, high-efficacy strategy. By narrowing the target population to those with specific biomarker expression, Oculis is attempting to mitigate the risks associated with broad-market competition. The company is also leveraging its current liquidity to advance its neurology pipeline through the end of the decade.